Professor Daniel M Berney

MB B Chir, MA, FRCPath
Honorary Professor of Genito-urinary Pathology; Consultant Pathologist
Group Leader
Research Focus

My focus is on the pathology and natural history of prostate, testicular and penile cancer working to translate basic research into practical treatments for patients with novel tests and bespoke predictive treatments.

Key Publications
Pathological predictors of metastatic disease in testicular non-seminomatous germ cell tumors: which tumor-node-metastasis staging system? Mod Pathol (2021) 34(4):834-841. PMID: 33319858.

Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study. Lancet Oncol (2020) 21(2):222-232. PMID: 31926806

Alternative HER/PTEN/Akt pathway activation in HPV positive and negative penile carcinomas. PLoS One (2011) 6(3):e17517. PMID: 21407808.

Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol (2011) 12(3):245-55. PMID: 21310658.

Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. Br J Cancer (2009) 100(6):888-93. PMID: 19293807.
Major Funding
  • Orchid
  • Prostate Cancer UK
  • Barts Cancer Charity
  • Cancer Research UK
Other Activities
  • Editor in Chief of Histopathology
Research

Professor Berney is an internationally recognised pathology expert in the three male GU cancers. He works at the Royal London Hospital and receives referrals nationally and internationally for his opinion. He is co Editor of the next WHO classification of GU cancers, and has published over 270 papers, with an H score of 71 and over 20,000 citations. He is editor in Chief of ‘Histopathology’, the leading general pathology journal in Europe.

He has helped to pioneer changes in the grading of prostate cancer, and two new tests to work out disease aggressiveness. In testis cancer he is helping refine decisions on adjuvant chemotherapy and treatment in early disease and has helped identify cases which are now known to be benign but were previously thought to be malignant.

He is now working on refining treatment and oncological decisions in advanced prostate cancer, working with Pressor Attard at UCL, using the 10,000 strong STAMPEDE trial and with a Danish group on the treatment of testicular cancer.

Other Activities
  • Editor in Chief of Histopathology
Major Funding
  • Orchid
  • Prostate Cancer UK
  • Barts Cancer Charity
  • Cancer Research UK
Biography
Professor Berney was trained at Jesus College Cambridge and has a 1st class degree. He joined the Royal London Hospital in 1991 and was appointed consultant in 1998.

He now divides his time between Genito-urinary pathology at Barts Health NHS Trust and research as Professor and Principal Investigator at the Barts Cancer Institute, Queen Mary University of London. He heads the Orchid Tissue Bank, an internationally significant resource for cancer research analysis. His research is continuing and expanding on the work commenced by one of Orchid’s founders, Professor Tim Oliver, and encompasses the histopathology of all three male-specific cancers; prostate, testis and penile. Professor Berney has been the Chairman of the Association of Uro-Pathologists (BAUP) and Secretary of the International Society of urological pathologists. He is also Editor in Chief of Histopathology (Impact factor 5.1). He was appointed NHS Professor of Genito-urinary pathology in October 2012.